NCT07260760|Not Yet Recruiting
Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke
Ischemic strok
Loading search results
Ischemic strok
Sponsor study identifier
observational
600
0 countries
N/A
Study Start
January 20, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study conducted a comprehensive evaluation of commonly used neuroprotective agents in acute ischemic stroke, assessing their real-world value across six dimensions: safety, efficacy, cost-effectiveness, innovativeness, appropriateness, and accessibility. Employing a prospective observational design, it primarily investigates the association of edaravone and dexrazoxane with clinical outcomes in patients with mild-to-moderate stroke, with subgroup analyses performed according to Trial of Org 10172 in Acute Stroke Treatment （TOAST ）classification.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 20, 2025
Actual (reported)December 3, 2025
Actual (reported)January 20, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Proportion of patients with Modified Rankin Scale（mRS ）scores of 0-1
90 days
Proportion of patients with mRS scores of 0-2
30 days
Percentage reduction in National Institutes of Health Stroke Scale （NIHSS ）score compared to pre-treatment
90 days after medication
Patients with ischemic stroke
Fu Y, Wang A, Tang R, Li S, Tian X, Xia X, Ren J, Yang S, Chen R, Zhu S, Feng X, Yao J, Wei Y, Dong X, Ling Y, Yi F, Deng Q, Guo C, Sui Y, Han S, Wen G, Li C, Dong A, Sun X, Wang Z, Shi X, Liu B, Fan D. Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial. JAMA Neurol. 2024 Feb 19;81(4):319-26. doi: 10.1001/jamaneurol.2023.5716. Online ahead of print.
Xiaofang Niu
Heze Municipal Hospital
Leqing Zhang
Yanggu County People's Hospital
Lei Duan
Zibo Central Hospital
Kai Ren
Haiyang People's Hospital
First Submitted
November 20, 2025
First Posted
December 3, 2025
Study Start
January 20, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
Contact the study team to confirm eligibility.
Rongrong Zhang
Sishui County People's Hospital
Ping Yang
Jinan Fourth People's Hospital
Ning Liu
Shandong Hospital of Integrated Traditional Chinese and Western Medicine
Pengcheng Du
Qilu Hospital of Shandong University, Dezhou Branch
Hui Liu
Jinan Municipal People's Hospital
Xi Rong
Weifang Yidu Central Hospital
Deyin Zhai
Linyi Traditional Chinese Medicine Hospital
Zhiqiang Zhang
Anqiu People's Hospital
Jiyong Wu
Shandong Provincial Hospital
Meixia Wang
Jining Medical University Affiliated Hospital
Ping Wang
Liaocheng People's Hospital
Jiyao Li
Liaocheng Municipal People's Hospital
December 31, 2028
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
January 15, 2026
Record last verified: 2026-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: